All Stories

  1. The Effects of Long-Term High Fat and/or High Sugar Feeding on Sources of Postprandial Hepatic Glycogen and Triglyceride Synthesis in Mice
  2. Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies
  3. Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery
  4. Clusters of adipose tissue dysfunction in adults with type 2 diabetes identify those with worse lipidomic profile despite similar glycaemic control
  5. Vagal activation alters prandial bile acid composition and glycemia in patients with hypoglycemia after Roux‐en‐Y gastric bypass surgery
  6. Hepatic glucose metabolism in the steatotic liver
  7. Methods to Study Metabolomics
  8. ForePass endoscopic bypass device for obesity and insulin resistance—metabolic treatment in a swine model
  9. Reflecting on a Year at the Helm of Diabetes Care
  10. Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
  11. Reduced Insulin Clearance Differently Relates to Increased Liver Lipid Content and Worse Glycemic Control in Recent-Onset Type 2 and Type 1 Diabetes
  12. GLP-1 enhances beta-cell response to protein ingestion independent of glycemia and bariatric surgery amplifies it
  13. Differential effect of gastric bypass versus sleeve gastrectomy on insulinotropic action of endogenous incretins
  14. Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk
  15. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
  16. Endogenous glucagon-like peptide 1 diminishes prandial glucose counterregulatory response to hypoglycemia after gastric bypass surgery
  17. Exposure profiles in pregnant women from a birth cohort in a highly contaminated area of southern Italy
  18. Plasma Amino Acids in NAFLD Patients with Obesity Are Associated with Steatosis and Fibrosis: Results from the MAST4HEALTH Study
  19. A global action agenda for turning the tide on fatty liver disease
  20. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
  21. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes
  22. Bariatric Surgery Alters the Postprandial Recovery From Hypoglycemia, Mediated by Cholinergic Signal
  23. Hunting for Progressive NAFLD in Type 2 Diabetes: Do Not Trust Liver Enzymes!
  24. Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts
  25. A global research priority agenda to advance public health responses to fatty liver disease
  26. Lipidomic Profiling Unveils Sex Differences in Diabetes Risk: Implications for Precision Medicine
  27. Plasma Amino Acids in NAFLD Patients With Obesity Are Associated With Steatosis and Fibrosis; Results From the MAST4HEALTH Study
  28. Role of Insulin Clearance in Insulin Action and Metabolic Diseases
  29. Insulinotropic effect of endogenous incretins is greater after gastric bypass than sleeve gastrectomy despite diminished beta-cell sensitivity to plasma incretins
  30. Insulin Clearance in Health and Disease
  31. Brain histone beta-hydroxybutyrylation couples metabolism with gene expression
  32. Higher Hepatic Glucose Production and Gluconeogenesis are Features of Severe Metabolic Dysfunction-Associated Steatohepatitis Even in Absence of T2D
  33. Responses to Lifestyle Intervention in Individuals at High Risk of Type 2 Diabetes Depend on Pre-Intervention Insulin Sensitivity and Secretion: A Machine Learning Analysis of DEXLIFE and EGIR-RISC Data
  34. “The Times They Are A-Changin’” at Diabetes Care
  35. Exposure to Endocrine Disruptors (Di(2-Ethylhexyl)phthalate (DEHP) and Bisphenol A (BPA)) in Women from Different Residing Areas in Italy: Data from the LIFE PERSUADED Project
  36. Exposure profiles in pregnant women from a birth cohort in a highly contaminated area of southern Italy
  37. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
  38. Enrichment of hepatic glycogen and plasma glucose from H₂18O informs gluconeogenic and indirect pathway fluxes in naturally feeding mice
  39. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes
  40. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals
  41. Measuring and estimating insulin resistance in clinical and research settings
  42. High exposure to phthalates is associated with HbA1c worsening in type 2 diabetes subjects with and without edentulism: a prospective pilot study
  43. Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions
  44. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
  45. 360-OR: Hyperglucagonemia Reduces De Novo Lipogenesis and Increases Gluconeogenesis in Healthy Subjects
  46. Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?—the results of the Pan-PPAR Lanifibranor trial
  47. 1298-P: Metabolic Clearance of Insulin Is Altered after Gastric Bypass and Sleeve Gastrectomy
  48. Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy
  49. 57-OR: Responses to Lifestyle Intervention (LI) Are Associated to the Inter-Individual Variability in Glucose Metabolism at Baseline for Individuals at High Risk of Type 2 Diabetes (T2D)
  50. Women exposure to Di(2-ethylhexyl)phthalate (DEHP) and bisphenol A (BPA) from different residing areas in Italy: data from the LIFE PERSUADED project
  51. Global multi-stakeholder endorsement of the MAFLD definition
  52. Advanced glycation end products, leukocyte telomere length, and mitochondrial DNA copy number in patients with coronary artery disease and alterations of glucose homeostasis: From the GENOCOR study
  53. Editorial: Mechanisms for the Alteration in the Crosstalk Among Insulin-Sensitive Tissues
  54. Insulin: The master regulator of glucose metabolism
  55. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose
  56. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
  57. Autoantibodies against the glial glutamate transporter GLT1/EAAT2 in Type 1 diabetes mellitus—Clues to novel immunological and non-immunological therapies
  58. Assessment of Exposure to Di-(2-ethylhexyl) Phthalate (DEHP) Metabolites and Bisphenol A (BPA) and Its Importance for the Prevention of Cardiometabolic Diseases
  59. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )
  60. Metabolic dysfunction-associated fatty liver disease: a year in review
  61. Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
  62. Adipose tissue dysfunction and visceral fat are associated to hepatic insulin resistance and severity of NASH even in lean individuals
  63. Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study
  64. Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction
  65. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
  66. Why does obesity cause diabetes?
  67. Women Exposure to Di(2-Ethylhexyl)Phthalate (Dehp) and Bisphenol a (Bpa) from Different Residing Areas in Italy: Data from the Life Persuaded Project
  68. Metabolite Changes After Metabolic Surgery – Associations to Parameters Reflecting Glucose Homeostasis and Lipid Levels
  69. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non‐alcoholic steatohepatitis
  70. Assessment of exposure to Di (2-ethylhexyl) phthalate (DEHP) metabolites and Bisphenol A (BPA) and its importance for the prevention of cardiometabolic diseases
  71. Disparity-filtered differential correlation network analysis: a case study on CRC metabolomics
  72. Italian Children Exposure to Bisphenol A: Biomonitoring Data from the LIFE PERSUADED Project
  73. Assessment of RANKL/RANK/osteoprotegerin system expression in patients with hepatocellular carcinoma
  74. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis
  75. An extra virgin olive oil‐enriched chocolate spread positively modulates insulin‐resistance markers compared with a palm oil‐enriched one in healthy young adults: A double‐blind, cross‐over, randomised controlled trial
  76. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
  77. Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action
  78. New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms
  79. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
  80. PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
  81. 125-LB: Differential Influences of Gastric Bypass and Sleeve Gastrectomy on Glucose-Reducing Effects of DPP-4 Inhibitor
  82. 215-LB: The Role of GLP-1 in Glycemic Response to Protein Ingestion after Gastric Bypass Surgery or Sleeve Gastrectomy
  83. Changes in Plasma Bioactive Lipids and Inflammatory Markers during a Half-Marathon in Trained Athletes
  84. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
  85. Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD
  86. Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
  87. Toxicological Assessment of Oral Co-Exposure to Bisphenol A (BPA) and Bis(2-ethylhexyl) Phthalate (DEHP) in Juvenile Rats at Environmentally Relevant Dose Levels: Evaluation of the Synergic, Additive or Antagonistic Effects
  88. Liver-targeting drugs and their effect on blood glucose and hepatic lipids
  89. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models
  90. Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial
  91. External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study
  92. Metabolic, reproductive and thyroid effects of bis(2-ethylhexyl) phthalate (DEHP) orally administered to male and female juvenile rats at dose levels derived from children biomonitoring study
  93. Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity
  94. SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial
  95. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
  96. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models
  97. The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes
  98. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
  99. Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance
  100. COVID-19 Infection Pandemic: From the Frontline in Italy
  101. Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects
  102. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase
  103. Small intestinal metabolism is central to whole-body insulin resistance
  104. Effects of Probiotic Supplementation on Gastrointestinal, Sensory and Core Symptoms in Autism Spectrum Disorders: A Randomized Controlled Trial
  105. The Pro12Ala polymorphism of PPARγ2 modulates beta cell function and failure to oral glucose‐lowering drugs in patients with type 2 diabetes
  106. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
  107. Mechanisms for increased risk of diabetes in chronic liver diseases
  108. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?
  109. Relationship between hepatic and systemic angiopoietin‐like 3, hepatic Vitamin D receptor expression and NAFLD in obesity
  110. 153-OR: Glucose-Dependency of Insulinotropic and Glucagonostatic Effects of Glucagon-Like Peptide-1 after Gastric Bypass and Sleeve Gastrectomy
  111. 1774-P: Neurally Mediated Prandial Islet-Cell Function Is Glucose-Independent and Preserved after Gastric Bypass and Sleeve Gastrectomy
  112. 1836-P: Nonalcoholic Steatohepatitis (NASH) Significantly Contribute to ß-Cell Function Impairment Independently of Glucose Tolerance Status
  113. 352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study
  114. Biomonitoring of Bis(2-ethylhexyl)phthalate (DEHP) in Italian children and adolescents: Data from LIFE PERSUADED project
  115. The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue
  116. Insulin sensitivity depends on the route of glucose administration
  117. Biomarkers of exposure and early effect in three contaminated sites of southern Italy: protocols for etiological epidemiological studies
  118. Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk
  119. Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study
  120. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease
  121. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion
  122. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications
  123. Fatty liver, cardiometabolic disease and mortality
  124. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD
  125. Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
  126. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
  127. Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects
  128. Healthy aging: the INTECMAN project
  129. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity
  130. Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease
  131. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
  132. Inflammatory Biomarkers are Correlated with Some Forms of Regressive Autism Spectrum Disorder
  133. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy?
  134. Juvenile Toxicity Rodent Model to Study Toxicological Effects of Bisphenol A (BPA) at Dose Levels Derived From Italian Children Biomonitoring Study
  135. Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis
  136. Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas
  137. Association of serum lipids with β-cell function in obese children and adolescents
  138. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
  139. Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity
  140. 27th Annual Meeting of the European Group for the study of Insulin Resistance, Lisbon, Portugal, 8–9th May 2019
  141. Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
  142. The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake
  143. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD
  144. Insulin resistance, liver inflammation and fibrosis in patients with NAFLD
  145. Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis
  146. Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity
  147. 155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion
  148. 1888-P: Impaired Insulin Clearance Relates to Increased Liver Fat Content in Recent-Onset Type 2 Diabetes and to Impaired Glucose Control in Recent-Onset Type 1 Diabetes
  149. 245-OR: Glucose Production and Utilization following Oral Glucose Load in Type 2 Diabetes Patients Treated with Dapagliflozin Alone and in Saxagliptin Combination
  150. Osteoprotegerin as optimal target for the screening of patients with hepatocellular carcinoma at higher risk of mortality
  151. Reduced insulin clearance relates to increased liver fat content in recent-onset type 2 diabetes and to impaired glucose control in recent-onset type 1 diabetes
  152. FRI-283-Impact on NAFLD of long-term weight loss after bariatric surgery
  153. PS-006-MBOAT7 downregulation induces hepatic lipid accumulation
  154. SAT-290-Association of liver inflammation and fibrosis score with noninvasive biomarkers in non-alcoholic fatty liver disease: Preliminary results from the MAST4HEALTH study
  155. SAT-323-Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease
  156. Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemia
  157. Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery
  158. Women-specific predictors of cardiovascular disease risk - new paradigms
  159. Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet
  160. Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease
  161. Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, Papio sp.
  162. Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study
  163. Phthalates exposure as determinant of albuminuria in type 2 diabetes subjects: a cross-sectional study
  164. Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans
  165. The LIFE PERSUADED project approach on phthalates and bisphenol A biomonitoring in Italian mother-child pairs linking exposure and juvenile diseases
  166. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars
  167. Publisher Correction: Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery
  168. Beneficial Effects of RYGB on ß-Cell Function and Hepatic and Peripheral Insulin Sensitivity Are Maintained Seven Years after Surgery in Both Diabetic and Nondiabetic Subjects
  169. Lean Subjects with Fatty Liver Show Decreased GLP-1 and GIP Response during OGTT
  170. Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release
  171. Bile acid composition modulate insulin resistance in non-diabetic patients with NAFLD
  172. Impact of short term weight loss (very low calorie diet vs bariatric surgery) on hepatic insulin resistance and plasma lipidomic profile
  173. In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease
  174. Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients
  175. Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars
  176. Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research
  177. Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study
  178. Bile acid composition modulates insulin resistance in non-diabetic patients with NAFLD
  179. Reply
  180. The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF
  181. Beta-cell sensitivity to glucose is impaired after gastric bypass surgery
  182. Author Correction: Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
  183. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
  184. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
  185. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up
  186. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
  187. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
  188. Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery
  189. Correction
  190. The color of fat and its central role in the development and progression of metabolic diseases
  191. Glucose kinetics
  192. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study
  193. An extended fatty liver index to predict non-alcoholic fatty liver disease
  194. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
  195. Response to Comment on Gastaldelli et al. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care 2016;39:1925–1931
  196. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies
  197. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes
  198. Increased FNDC5/Irisin expression in human hepatocellular carcinoma
  199. Increased hepatic glucose production and insulin resistance are associated to increased plasma concentrations of glucogenic amino acids in subjects with NAFLD
  200. The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and NAFLD progression in mice lacking NLRP3-inflammasome
  201. Hepatic Insulin Resistance and Altered Gluconeogenic Pathway in Premature Baboons
  202. Chronic Intranasal Insulin Does Not Affect Hepatic Lipids but Lowers Circulating BCAAs in Healthy Male Subjects
  203. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients
  204. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study
  205. Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids
  206. The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and non-alcoholic fatty liver disease progression in mice lacking NLRP3-inflammasome
  207. Response to: Drug therapy for ectopic fat: myth or reality?
  208. Pathophysiology of Non Alcoholic Fatty Liver Disease
  209. Ectopic fat: a target for cardiometabolic risk management
  210. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
  211. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
  212. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass
  213. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
  214. Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1
  215. Glucose uptake saturation explains glucose kinetics profiles measured by different tests
  216. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
  217. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
  218. Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
  219. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial
  220. Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
  221. Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
  222. Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease
  223. Lack of NLRP3-inflammasome leads to gut-liver axis derangement and increases hepatic injury in a mouse model of NAFLD
  224. Early effect of Roux-en-Y gastric bypass on insulin sensitivity and signaling
  225. Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease
  226. Angiopoietin-Like4 is Associated with Lipid Metabolism and Severe Fibrosis in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease
  227. Evaluation of Metabolic Parameters of Hepatic Dysfunction in Subjects with Hepatocellular Carcinoma and their Change after Liver Transplantation: A Metabolomic Approach
  228. Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance
  229. Lack of NLRP3-Inflammasome Leads to Gut-Liver AXIS Derangement and Increases Hepatic Injury in a Mouse Model of Non-Alcoholic Fatty Liver Disease
  230. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
  231. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
  232. Brown versus white fat: are they really playing a role in obesity and cardiometabolic risk?
  233. Obesity and carotid artery remodeling
  234. Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant
  235. Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
  236. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
  237. P1042 : Deregulation of de novo lipogenesis can be associated with liver damage in patients with non alcoholic fatty liver disease
  238. O064 : Gut-liver axis derangement due to lack of inflammasome activity leads to visceral obesity and nash development
  239. P1056 : Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with nonalcoholic fatty liver disease, independently of diabetes, hypertension and dyslipidemia
  240. P0519 : Lipidomics reveals that low plasma unsaturated to saturated fat ratios are biomarkers of NAFLD and liver damage
  241. Peripheral Insulin Resistance and Impaired Insulin Signaling Contribute to Abnormal Glucose Metabolism in Preterm Baboons
  242. Gut–liver axis derangement due to lack of inflammasome activity leads to visceral obesity and NASH development
  243. Liver damage can be associated with deregulation of the de novo lipogenesis pathway in subjects with Non Alcoholic Fatty Liver Disease
  244. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal musclein vivo
  245. Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases
  246. Neurophysiological and Behavioural Variables in Cognitive Impairment: Towards a Personalised Monitoring System
  247. Corrigendum to “Insulin resistance, adipose depots and gut: Interactions and pathological implications” [Dig. Liver Dis. 42 (2010) 310–319]
  248. Risk Relationship between Insulin Resistance, Diabetes, and Atherosclerotic Cardiovascular Disease
  249. The Disposition Index Does Not Reflect β-Cell Function in IGT Subjects Treated With Pioglitazone
  250. The good and bad effects of statins on insulin sensitivity and secretion
  251. Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study
  252. Pathophysiology of Prediabetes: Role of Lipotoxicity?
  253. Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women
  254. Altered Islet Function and Insulin Clearance Cause Hyperinsulinemia in Gastric Bypass Patients With Symptoms of Postprandial Hypoglycemia
  255. Matched weight loss induced by sleeve gastrectomy or gastric bypass similarly improves metabolic function in obese subjects
  256. HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
  257. Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion
  258. Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance
  259. Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
  260. P857 A NEW INDEX OF GLUTATHIONE TURNOVER (GSH_TI) AND ITS ASSOCIATION WITH SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
  261. P843 ALTERATION IN GLUCOSE METABOLISM AFTER AN ORAL GLUCOSE LOAD AND RELATIONSHIP WITH LIVER DAMAGE IN PATIENTS WITH NAFLD
  262. P840 ALTERATION IN LIPID METABOLISM AFTER AN ORAL FAT LOAD IN PATIENTS WITH NAFLD
  263. P845 IMPACT OF FAT VERSUS GLUCOSE LOAD ON OXIDATIVE STRESS IN NON-ALCOHOLIC FATTY LIVER DISEASE
  264. P849 QUANTITATIVE AND QUALITATIVE ANALYSIS OF PLASMA FREE FATTY ACIDS AND THEIR IMPACT ON LIVER DAMAGE IN NAFLD PATIENTS
  265. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic
  266. Blockade of Glucagon-like Peptide 1 Receptor Corrects Postprandial Hypoglycemia After Gastric Bypass
  267. Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease
  268. Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease
  269. Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease
  270. Visceral Adipose Tissue and Ectopic Fat Deposition
  271. Motor Activity in Aging: An Integrated Approach for Better Quality of Life
  272. Albiglutide for the treatment of type 2 diabetes mellitus
  273. Moving Medical Semeiotics to the Digital Realm - SEMEOTICONS Approach to Face Signs of Cardiometabolic Risk
  274. Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk
  275. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes
  276. Metabolic Consequences of Adipose Triglyceride Lipase Deficiency in Humans: An In Vivo Study in Patients With Neutral Lipid Storage Disease With Myopathy
  277. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment
  278. Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction
  279. Ectopic fat: the true culprit linking obesity and cardiovascular disease?
  280. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT
  281. Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
  282. Long-Term Effects of Bariatric Surgery on Meal Disposal and  -Cell Function in Diabetic and Nondiabetic Patients
  283. Biliopancreatic Diversion in Nonobese Patients With Type 2 Diabetes: Impact and Mechanisms
  284. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study
  285. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
  286. The effect of chronic twice daily exenatide treatment on β‐cell function in new onset type 2 diabetes
  287. 1351 CONTRIBUTION OF VISCERAL FAT AND HEPATIC FAT TO METABOLIC DERANGEMENTS AND LIVER DAMAGE IN NAFLD PATIENTS
  288. 73 KR ÜPPEL LIKE FACTOR 6 (KLF6) PROTECTS FROM NAFLD PROGRESSION THROUGH REGULATION OF ADIPOSE TISSUE INSULIN RESISTANCE
  289. 1365 METABOLIC ALTERATIONS OF LIPID KINETICS IN NAFLD PATIENTS AND THEIR CONTRIBUTION TO LIVER DAMAGE
  290. Imaging cardiac fat
  291. Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver
  292. Importance of liver fat indices for diagnosis of hepatic steatosis
  293. Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
  294. Validation of [18F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity
  295. A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis
  296. Metabolic response to high-carbohydrate and low-carbohydrate meals in a nonhuman primate model
  297. Gastric bypass and banding equally improve insulin sensitivity and β cell function
  298. The role of cardiac fat in insulin resistance
  299. Dynamics of Circulating Ligands and Soluble Receptor for Advanced Glycation End-Product in Liver Transplantation
  300. Dynamics of Circulating Ligands and Soluble Receptor for Advanced Glycation End-Product in Liver Transplantation
  301. Direct effect of GLP-1 infusion on endogenous glucose production in humans
  302. Hepatic and Cardiac Steatosis
  303. Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
  304. Effects of Adding Exercise to a 16-Week Very Low-Calorie Diet in Obese, Insulin-Dependent Type 2 Diabetes Mellitus Patients
  305. The ontogeny of the endocrine pancreas in the fetal/newborn baboon
  306. Integrated Physiology/Obesity
  307. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques
  308. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease
  309. 1310 PERIPHERAL INSULIN RESISTANCE RATHER THAN HEPATIC IS A PRIMARY DEFECT IN NON OBESE, NON DIABETIC, NON DYSLIPIDEMIC NAFLD PATIENTS: CORRELATION WITH LIVER DAMAGE
  310. 1290 THE EFFECT OF EXERCISE ON THE METABOLIC AND HISTOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE
  311. 215 THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (RAGE) AXIS IN LIVER TRANSPLANTATION
  312. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
  313. Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models
  314. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease
  315. Fatty Liver Index Predicts Further Metabolic Deteriorations in Women with Previous Gestational Diabetes
  316. Relationship between fatty liver and glucose metabolism: A cross-sectional study in 571 obese children
  317. Diabetes and Nonalcoholic Fatty Liver Disease
  318. Diet and Exercise in the Treatment of Fatty Liver
  319. Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates
  320. Pericardial Rather Than Epicardial Fat is a Cardiometabolic Risk Marker: An MRI vs Echo Study
  321. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population
  322. Metabolic effects of muraglitazar in type 2 diabetic subjects
  323. Ectopic Fat Storage, Insulin Resistance, and Hypertension
  324. Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in Humans
  325. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus
  326. Protective role of adiponectin on endothelial dysfunction induced by AGEs: A clinical and experimental approach
  327. Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
  328. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes
  329. What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?
  330. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans
  331. Liver Enzymes Are Associated With Hepatic Insulin Resistance, Insulin Secretion, and Glucagon Concentration in Healthy Men and Women
  332. Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
  333. Pathophysiology of Prediabetes
  334. 1264 CRITICAL ROLE OF TRIGLYCERIDES AND LONG CHAIN FATTY ACYL COA ACCUMULATION IN LIVER INSULIN RESISTANCE IN THE BABOON. A NEW NON-HUMAN PRIMATE MODEL OF NAFLD
  335. 842 PREDISPOSITION TO DEVELOP DIABETES IN SUBJECTS WITH NAFLD IS RELATED TO INSULIN RESISTANCE RATHER THAN TO DECREASED B-CELL FUNCTION
  336. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
  337. Mechanism and Effects of Glucose Absorption during an Oral Glucose Tolerance Test Among Females and Males
  338. Ectopic fat and cardiovascular disease: What is the link?
  339. Effect of Oral Sebacic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes
  340. ORIGINAL ARTICLE: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study
  341. Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
  342. Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial
  343. Pioglitazone in the treatment of NASH: the role of adiponectin
  344. Fatty liver disease: the hepatic manifestation of metabolic syndrome
  345. Insulin resistance, adipose depots and gut: Interactions and pathological implications
  346. 340 FATTY LIVER INDEX (FLI) IS AN INDEPENDENT PREDICTOR OF CHANGES IN METABOLIC AND CARDIOVASCULAR PARAMETERS: RESULTS FROM A 3-YEAR FOLLOW UP IN THE RISC STUDY
  347. 82 KRUPPEL LIKE FACTOR 6 (KLF6) REGULATES HEAPTIC INSULIN RESISTANCE (HEP-IR)
  348. Acute effects of gastric bypass versus gastric restrictive surgery on β-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes
  349. A new approach to study in vivo cellular metabolism using a modellistic analysis of magnetic resonance spectra
  350. Pancreatic islet amyloidosis, β-cell apoptosis, and α-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons
  351. Reply:
  352. Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms
  353. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
  354. Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study
  355. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
  356. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
  357. Imaging and Laboratory Biomarkers in Cardiovascular Disease
  358. The Effect of Menopause on Carotid Artery Remodeling, Insulin Sensitivity, and Plasma Adiponectin in Healthy Women
  359. 346 INCREASED LIVER EXPRESSION OF INFLAMMATORY MEDIATORS IS ASSOCIATED WITH HEPATIC INSULIN RESISTANCE IN LEAN, NON-DIABETIC PATIENTS WITH CHRONIC HEPATITIS C
  360. 55 METABOLIC AND ANTI-INFLAMMATORY BENEFICIAL EFFECTS OF PIOGLITAZONE (PIO) TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND THEIR ASSOCIATIONS WITH HISTOLOGICAL IMPROVEMENT
  361. Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh
  362. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice
  363. Hepatic fat is not associated with β-cell function or postprandial free fatty acid response
  364. Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats
  365. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population
  366. Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons.
  367. The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
  368. Elevated Concentrations of Liver Enzymes and Ferritin Identify a New Phenotype of Insulin Resistance: Effect of Weight Loss After Gastric Banding
  369. Automatic correction of intensity inhomogeneities improves unsupervised assessment of abdominal fat by MRI
  370. Abdominal fat: does it predict the development of type 2 diabetes?
  371. Intra-abdominal adiposity, abdominal obesity, and cardiometabolic risk
  372. Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test
  373. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
  374. Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects
  375. Early Hypertension Is Associated With Reduced Regional Cardiac Function, Insulin Resistance, Epicardial, and Visceral Fat
  376. 36 FATTY LIVER INDEX IS ASSOCIATED WITH INCREASED INSULIN RESISTANCE AND CAROTID INTIMA MEDIA THICKNESS (IMT) IN NONDIABETIC SUBJECTS: THE RISC STUDY
  377. Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients
  378. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach
  379. Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients
  380. Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women
  381. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy
  382. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
  383. Insulin Resistance, Insulin Response, and Obesity as Indicators of Metabolic Risk
  384. Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects
  385. Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training
  386. Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus
  387. Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes
  388. Quantification of Liver Glucose Metabolism by Positron Emission Tomography: Validation Study in Pigs
  389. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes
  390. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
  391. Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein
  392. Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea
  393. Thiazolidinediones improve beta-cell function in type 2 diabetic patients
  394. The Effect of Pioglitazone on the Liver: Role of adiponectin
  395. O-210
  396. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome
  397. [11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia
  398. The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
  399. Pathogenesis and Clinical Features of Obesity and Insulin Resistance
  400. ANALYSIS OF DOUBLE-TRACER GLUCOSE KINETICS IN HUMANS DURING ORAL GLUCOSE TOLERANCE TEST
  401. Visceral fat and beta cell function in non-diabetic humans
  402.  -Cell Function in Morbidly Obese Subjects During Free Living: Long-Term Effects of Weight Loss
  403. Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity
  404.  -Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide
  405. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
  406. β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
  407. Beta-Cell Function in Obesity: Effects of Weight Loss
  408. Characterization of  -cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests
  409. re: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31?39
  410. Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31?39
  411. Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis
  412. Visceral Fat in Hypertension: Influence on Insulin Resistance and  -Cell Function
  413. Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes
  414. An accurate and robust method for unsupervised assessment of abdominal fat by MRI
  415. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
  416. 60 Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis
  417. A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes
  418. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance
  419. Influence of Ethnicity and Familial Diabetes on Glucose Tolerance and Insulin Action: A Physiological Analysis
  420. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects
  421. Metabolic Effects of Visceral Fat Accumulation in Type 2 Diabetes
  422. Assessing Insulin Secretion by Modeling in Multiple-Meal Tests: Role of Potentiation
  423. Effect of Acute Hyperglycemia on Insulin Secretion in Humans
  424. Determination of the Enrichment of the Hydrogen Bound to Carbon 5 of Glucose on 2H2O Administration
  425. Effect of Physiological Hyperinsulinemia on Gluconeogenesis in Nondiabetic Subjects and in Type 2 Diabetic Patients
  426. A model for assessing insulin secretion and its control under free-living conditions
  427. A model for glucose control of insulin secretion during 24 h of free living.
  428. Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity
  429. Insulin prolongs the QTc interval in humans
  430. Determinants of postabsorptive endogenous glucose output in non-diabetic subjects
  431. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.
  432. Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach
  433. A Model for Assessing Insulin Secretion Function During a 24 Hour Standardized Life Period
  434. Fat metabolism during high-intensity exercise in endurance-trained and untrained men
  435. Modelling Interpretation of the Kinetics of Metabolic Processes
  436. Assessment of methods for improving tracer estimation of non-steady-state rate of appearance
  437. Insulin: new roles for an ancient hormone
  438. A modellistic view of the kinetics of metabolic processes: differences in the glucose and xylose degradation pathway
  439. Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency
  440. Linear and Nonlinear Properties of Heart Rate Variability: Influence of Obesity
  441. Splanchnic and leg substrate exchange after ingestion of a natural mixed meal in humans
  442. Autonomic and Hemodynamic Responses to Insulin in Lean and Obese Humans
  443. Influence of duration of obesity on the insulin resistance of obese non-diabetic patients
  444. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes
  445. Regulation of glucose production during exercise at 80% of VO2peak in untrained humans
  446. Energy expenditure of swimmers during high volume training
  447. Glucose kinetics in interstitial fluid can be predicted by compartmental modeling
  448. Kinetic Analysis and Comparison of Models of Xylose Metabolism byKlebsiella planticola
  449. Modeling Interpretation of Microbe Metabolism Detected by Nuclear Magnetic Resonance
  450. Effect of theophylline on substrate metabolism during exercise
  451. Lipid and carbohydrate metabolism in IDDM during moderate and intense exercise
  452. Lipid and Carbohydrate Metabolism in IDDM During Moderate and Intense Exercise
  453. Pathway of free fatty acid oxidation in human subjects. Implications for tracer studies.
  454. Protein synthesis and breakdown in skin and muscle: a leg model of amino acid kinetics
  455. 850 PATHWAY OF PLASMA FFA OXIDATION DURING EXERCISE
  456. A Leg Model of Amino Acid Kinetics in Skin and Muscle
  457. Changes in Tracer Infusion Rates to Minimize the Structure Error in the Steele’s Model
  458. An Energy Model for the Description of a Metabolic Process
  459. Pathway of Free Fatty Acid Oxidation
  460. Ross